Browse

Cytokinetics’ pill for a heart muscle disorder called hypertrophic cardiomyopathy could see its addressable market double after it succeeded in a pivotal trial for another form of the disease. The…

The British biotechnology startup is making "pan-gamma delta” T cell engagers it says can address the limitations of similar, existing therapies.

Vertex Pharmaceuticals said it has dropped development of an mRNA-based cystic fibrosis therapy after facing challenges similar to those that have troubled other parts of the field in delivering th…